Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Neoplasms 4 Prostatic Neoplasms 3 Lung Neoplasms 2 Carcinoma, Renal Cell 2 Weight Loss 1 Urinary Bladder Neoplasms 1 Triple Negative Breast Neoplasms 1 Sleep Apnea Syndromes 1 Sezary Syndrome 1 Sarcoma 1 Recurrence 1 Overweight 1 Obesity, Morbid 1 Obesity 1 Non-Muscle Invasive Bladder Neoplasms 1 Neoplasm Metastasis 1 Mycosis Fungoides 1 Multiple Myeloma 1 Lymphoma, T-Cell, Cutaneous 1 Hypertension 1 Hyperlipidemias 1 Hemangioma 1 Gastroesophageal Reflux 1 Eczema 1 Disease 1 Digestive System Diseases 1 Diabetes Mellitus, Type 2 1 Diabetes Mellitus 1 Dermatitis, Atopic 1 Collagen Diseases 1

Interventions

Doxorubicin 142 Ifosfamide 85 Radiotherapy 82 Cyclophosphamide 72 Gemcitabine 63 Filgrastim 54 pembrolizumab 43 pazopanib 40 Etoposide 39 Docetaxel 39 Vincristine 37 Trabectedin 37 Cisplatin 35 Nivolumab 32 Magnetic Resonance Spectroscopy 26 Irinotecan 26 Carboplatin 25 Temozolomide 23 Surgical Procedures, Operative 23 Radiation 22 Ipilimumab 22 Bevacizumab 20 Blood Specimen Collection 19 Granulocyte Colony-Stimulating Factor 18 Biopsy 18 eribulin 17 Sirolimus 17 Mesna 17 Melphalan 17 Dactinomycin 17

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Sarcoma × Urine Specimen Collection × Clear all

NCT06482957 2025-09-19

CAUSAL

Vanderbilt-Ingram Cancer Center

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡